The local anaesthetic lidocaine protects the myocardium in ischaemia±reperfusion situations. It is not known if this is the consequence of an anti-ischaemic effect or an effect on reperfusion injury. Therefore, we investigated the effect of two concentrations of lidocaine on myocardial ischaemia±reperfusion injury and on reperfusion injury alone. We used an isolated rat heart model where heart rate, ventricular volume and coronary¯ow were kept constant. Hearts underwent 45 min of low-¯ow ischaemia followed by 90 min reperfusion. Two groups received lidocaine 1.7 or 17 mg ml ±1 starting 5 min before the onset of reperfusion. In two additional groups, lidocaine infusion started 5 min before low-¯ow ischaemia. In all groups, lidocaine administration was stopped after 15 min of reperfusion. One group served as an untreated control (n=11 in each group). Left ventricular developed pressure (LVDP) and total creatine kinase release (CKR) were measured. Lidocaine administration during ischaemia and reperfusion led to an improved recovery of LVDP during reperfusion (1.7 mg ml 
Myocardial ischaemia can lead to cellular damage, not only during ischaemia itself, but also during subsequent reperfusion. Reperfusion injury can be reduced by modifying conditions of reperfusion.
1 One major aim of therapy for myocardial ischaemia is to limit infarct size by restoring coronary blood¯ow.
2 Several drugs reduce myocardial ischaemia±reperfusion injury further. When administering these drugs, it is important to know if they are protective only when given during ischaemia or if they are still protective when given after ischaemia during reperfusion. An example is the volatile anaesthetic halothane, which has greater protective effect against reperfusion injury than against ischaemic injury in isolated hearts. 3 Lidocaine is often used as an anti-arrhythmic drug in ischaemia±reperfusion situations. Besides having antiarrhythmic effects, lidocaine may protect myocardium not only against ischaemic but also against reperfusion injury by affecting intracellular concentrations of sodium 4 5 and calcium 6 7 during ischaemia and reperfusion, by protecting cellular membranes against long-chain acylcarnitines 8 and reactive oxygen species, 9 and perhaps by blocking calcium channels. 10 11 Lidocaine reduces myocardial ischaemia± reperfusion injury in isolated rat heart 12±14 and in vivo (in rabbit, 15 cat, 16 pig, 17 18 and dog 19±22 ). In all these studies, lidocaine administration started before or early during ischaemia. The question whether the cardioprotective effect of lidocaine is a consequence of anti-ischaemic properties or whether lidocaine can reduce myocardial reperfusion injury could not be answered by these studies. The present study was designed to determine if lidocaine reduces ischaemic or reperfusion injury, or both.
We used an isolated rat heart model with 45 min of lowow ischaemia and 90 min of reperfusion. A clinically relevant concentration of lidocaine and a 10-fold higher concentration were administered either during ischaemia and early reperfusion or during early reperfusion alone.
Methods
The study was performed in accordance with the regulations of the German Animal Protection Law and local institutional regulations.
Preparation of the isolated rat heart model used in this study has been described in detail previously. 3 In brief, isolated hearts from male Wistar rats were perfused in a Langendorff preparation with Krebs±Ringer solution at a constant¯ow rate of 14 ml min ±1 . Heart rate was maintained at 374 beats min ±1 . For measurement of left ventricular pressure (LVP), a latex balloon (size no. 5; Hugo Sachs Elektronik, March, Germany) was introduced into the left ventricle via the cut mitral valve. The balloon was ®xed at the tip of a stainless steel cannula which was connected directly to a P23 pressure transducer (Gould, Cleveland, OH, USA). At the beginning of each experiment, the latex balloon was ®lled, air-bubble free, with Krebs±Henseleit buffer resulting in a left ventricular end-diastolic pressure (LVEDP) of 10±12 mm Hg, and the volume was kept constant throughout the experiment. Coronary perfusion pressure (CPP) was also measured using a Gould P23 pressure transducer. Aliquots from the perfusion medium and the coronary venous ef¯uent perfusate were sampled and further processed in order to determine myocardial oxygen consumption and creatine kinase (CK) activity at different times during the experimental course, as markers of cellular damage. Total cumulative CK release was assessed by determining area under the curve. Figure 1 shows the experimental protocol used for the different groups. After preparation, a stabilization period of 20 min was allowed. Baseline measurements were then performed. Low-¯ow ischaemia was initiated by reducing coronary¯ow from 14 to 0.5 ml min ±1 and maintained for 45 min; 90 min of reperfusion (14 ml min ±1 ) followed. Samples for measurement of CK activity were collected 5 min before low-¯ow ischaemia, immediately before lowow ischaemia, after 20, 30 and 40 min of ischaemia, and 1, 3, 5, 10, 15, 20, 30, 45, 60 and 90 min after the onset of reperfusion.
Experimental protocol
Five groups (n=11 in each) and two lidocaine concentrations (1.7 and 17 mg ml ±1 ) were studied. To achieve lidocaine concentrations of 1.7 or 17 mg ml ±1 in the perfusate of lidocaine-treated hearts, a 100-fold higher concentration (0.17 or 1.7 mg ml ±1 ) was infused with a hundredth of the total¯ow (Model 5003 infusion pump; Precidior Infors, Basel, Switzerland). In two groups, the two lidocaine concentrations were administered during the last 5 min of low-¯ow ischaemia and during the ®rst 15 min of reperfusion. In two further groups, lidocaine infusion was started 5 min before low-¯ow ischaemia and stopped after 15 min of reperfusion. One group served as an untreated control.
Data analysis and statistics
LVP and CPP were continuously recorded on an ink recorder (Mark 260; Gould). The data were digitized using an analogue-to-digital converter (Data Translation, Marlboro, MA, USA) at a sampling rate of 500 Hz and processed on a personal computer. Twenty sequential cardiac cycles were averaged to compensate for variations. Left ventricular developed pressure (LVDP) as a variable of myocardial contractility was calculated by subtracting LVEDP from left ventricular systolic pressure. All data are expressed as mean (SEM). 
Lidocaine reduces ischaemic injury
For haemodynamic variables and myocardial oxygen consumption, statistical analysis was performed using analysis of variance (ANOVA). If ANOVA showed a group effect, Dunnett's test was used as a post hoc test at each measurement time. To detect group differences in cumulative CK release, ANOVA and Dunnett's post hoc test were performed. In the groups that received lidocaine during ischaemia and reperfusion, the pre-ischaemic effect of lidocaine was assessed using Student's t-test for paired values. All statistical calculations were performed with the original data; P-values of <0.05 were regarded as signi®cant.
Results
A total of 55 hearts, ful®lling prede®ned quality criteria (LVDP >80 mm Hg at CPP <100 mm Hg, and no ventricular ®brillation during the stabilization period), were included. CK samples for one heart in the control group were lost; all other data sets were complete. Heart weight was similar in all groups (1.14 (0.02) g, P=0.47±1.0 vs control).
Haemodynamic function
Under baseline conditions, haemodynamic variables were similar in all groups. Administration of lidocaine 1.7 mg ml ±1 before ischaemia had no signi®cant effect on any haemodynamic variable, while lidocaine 17 mg ml ±1 reduced LVDP and dP/dt max by 11 (2)% (P<0.01) and increased dP/dt min by 9 (1)% (P<0.05) and CPP by 19 (6)% (not statistically signi®cant, P=0.17).
During low-¯ow ischaemia, LVDP was similarly reduced in all groups, to 4.2 (0.3)% of baseline (P<0.001 vs baseline). In the control group and the groups that received lidocaine only during early reperfusion, LVDP recovered only slightly during reperfusion (control, 19.7 (3.4)% of baseline; 1.7 mg ml ±1 , 18.2 (6.4)% of baseline; 17 mg ml ±1 , 31.7 (6.7) % of baseline; after 30 min of reperfusion). Recovery of LVDP in the groups receiving lidocaine during ischaemia and reperfusion was signi®cantly improved (1.7 mg ml ±1 , 60.3 (11.8)% of baseline, P=0.012; 17 mg ml ±1 , 69.6 (10.3)% of baseline, P<0.001 vs control; after 30 min reperfusion). LVEDP increased during low-¯ow ischaemia in the control group and the groups that received lidocaine only during reperfusion (control, 272 (34)% of baseline; 1.7 mg ml ±1 , 251 (23)% of baseline; 17 mg ml ±1 , 320 (55)% of baseline). This increase was smaller in the groups that had received lidocaine during ischaemia and reperfusion (1.7 mg ml ±1 , 221 (44)% of baseline, P=0.001; 17 mg ml ±1 , 153 (26)% of baseline, P<0.001 vs control). During reperfusion, LVEDP in the groups that received lidocaine during ischaemia and early reperfusion was smaller than that in the control group (control, 528 (65)% of baseline; lidocaine during reperfusion: 1.7 mg ml ±1 , 605 (91)% of baseline, P=1.0; 17 mg ml ±1 , 505 (76)% of baseline, P=0.57; lidocaine during ischaemia and reperfusion: 1.7 mg ml ±1 , 194 (98)% of baseline, P=0.002; 17 mg ml ±1 , 180 (61)% of baseline, P<0.001 vs. control; after 30 min reperfusion).
Myocardial oxygen consumption
Myocardial oxygen consumption is shown in Figure 2 (bottom). After 90 min reperfusion, it was similar in the , and myocardial oxygen consumption (bottom) in the ®ve groups. Low-¯ow ischaemia led to a marked reduction in LVDP and an increase in LVEDP. During reperfusion, LVDP recovered more in the groups that received lidocaine during ischaemia and early reperfusion. In these groups, myocardial oxygen consumption was also higher during reperfusion than in the control group. Data are mean (SEM). *P<0.05, ²P<0.01, ³P<0.001 vs control. n=11 in each group. control group and the groups that received lidocaine only during early reperfusion (control 54 (6)% of baseline; 1.7 mg ml ±1 , 61 (8), P=0.86; 17 mg ml ±1 , 58 (7)% of baseline; P=1.0 vs control). In the groups that received lidocaine during ischaemia and reperfusion, myocardial oxygen consumption was signi®cantly higher at the end of the reperfusion period (1.7 mg ml ±1 , 85 (5)% of baseline, P=0.049; 17 mg ml ±1 , 85 (5)% of baseline, P=0.014 vs control)
Creatine kinase release Figure 3 shows cumulative CK release as variable of cellular damage. Administration of lidocaine only during early reperfusion had no signi®cant effect on CK release (1.7 mg ml ±1 , P=0.50; 17 mg ml ±1 , P=0.57 vs control). Lidocaine during ischaemia and early reperfusion reduced CK release by 39.4% (1.7 mg ml ±1 , P=0.042) and 60.2% (17 mg ml ±1 , P=0.001) compared with the control group.
Discussion
The cardioprotective effect of lidocaine in ischaemia± reperfusion situations has been demonstrated in several studies. The present study shows that cardioprotection by lidocaine is the consequence of an anti-ischaemic effect, but that lidocaine has no effect on reperfusion injury. Several mechanisms are discussed in the literature that may be responsible for this protective effect:
Reduction of intracellular sodium concentration
Myocardial ischaemia is accompanied by an increase in intracellular sodium concentration ([Na + ] i ). Sodium in¯ux 24 It has also been shown that lidocaine reduces ischaemic calcium loading.
6 7 Calcium overload is thought to be a major factor in reperfusion injury, 25 and lidocaine may reduce calcium overload by attenuating intracellular sodium overload.
Lidocaine as a calcium channel blocker
Calcium channel blockers are known to reduce ischaemic injury and myocardial reperfusion injury. 26 27 There is evidence that lidocaine acts as a calcium channel blocker, 10 11 and this may be another way in which it reduces calcium overload.
Protection of the cellular membrane
Destruction of the cellular membrane by reactive compounds generated during ischaemia and reperfusion is another important factor in ischaemia±reperfusion injury. Long-chain acylcarnitines participate in the production of ischaemia±reperfusion injury. 28 29 Oxygen free radicals generated particularly during the ®rst few minutes of reperfusion play an important role in the development of reperfusion injury by attacking fatty acids, which lead to lipid peroxidation of the cellular membrane. 2 30 Lidocaine protects myocardium from long-chain acylcarnitine-induced mechanical and metabolic derangement, 8 and is a powerful antioxidant which can scavenge oxygen free radicals. 9 
Negative inotropic effect of lidocaine
Negative inotropy may reduce myocardial oxygen consumption and, thereby, ischaemic injury. In addition, a complete or a partial contractile blockade at the onset of reperfusion can also reduce reperfusion injury. 31 32 These effects may only be relevant at higher concentrations of lidocaine at which it has negative inotropic effects. 33 Calcium overload and the destruction of cellular membrane by reactive oxygen species play a role in the development not only of ischaemic injury but also of myocardial reperfusion injury. Together with the known effects of lidocaine, these ®ndings indicate that the cardioprotection produced by lidocaine may at least in 
Control
Lidocaine during reperfusion Lidocaine during ischaemia and reperfusion Cumulative creatine kinase release in the ®ve groups. Lidocaine administered during ischaemia and early reperfusion reduced creatine kinase release. Lidocaine administration during reperfusion only had no effect on this marker of cellular damage. Data are mean (SEM). *P=0.042, ³P=0.001 vs control. n=10 in control group; n=11 in all other groups.
part be caused by an effect on myocardial reperfusion injury. In all studies showing cardioprotection by lidocaine against ischaemia±reperfusion injury, lidocaine was administered in a manner that did not allow effects on ischaemic injury to be distinguished from effects on reperfusion injury.
12±22 Therefore, it is unclear if late administration of lidocaine at the beginning of reperfusion can still be protective.
In the present study, lidocaine was administered at two concentrations during ischaemia and maintained during early reperfusion. In these two groups, functional recovery during reperfusion was improved (LVDP, dP/dt max ) accompanied by a smaller contracture (LVEDP) and a higher myocardial oxygen consumption, indicating a greater amount of viable myocardial tissue. CK release as a variable of cellular damage was reduced. These results demonstrate that lidocaine protects the myocardium from ischaemia± reperfusion injury in our model. The question of whether reduction of reperfusion injury contributes to this protective effect can be answered by looking at the two groups of our study which received lidocaine only during early reperfusion. While lidocaine administration during ischaemia and reperfusion was clearly cardioprotective, no protection was observed when lidocaine was given only during reperfusion: there was no improvement of functional recovery (LVDP, dP/dt max ), myocardial oxygen consumption was similar to that in the control group, myocardial contracture (LVEDP) was unchanged, and no reduction in cellular damage was detected (as assessed by CK release). In the group that received lidocaine at the higher concentration during reperfusion, there was a tendency to better functional recovery, lower contracture and reduced CK release. This effect was not statistically signi®cant and occurred at a very high lidocaine concentration. However, if there is an effect of lidocaine at this high concentration on myocardial reperfusion injury, this effect is very small and of little clinical relevance.
Our study shows that lidocaine protects the isolated rat heart in an ischaemia±reperfusion situation, but reduction of reperfusion injury does not contribute to this protective effect. While lidocaine given during ischaemia with the resulting reduction in [Na + ] i probably protected myocardium from ischaemic injury, the antioxidant effect of lidocaine, and its effect on intracellular calcium concentrationÐeither indirect (by reduction of Na + /Ca 2+ exchange) or direct (by its possible calcium channel blocking properties)Ðwere not suf®cient to protect the hearts against reperfusion injury.
Critique of methods
We used lidocaine at concentrations of 1.7 and 17 mg ml ±1 . Therapeutic plasma concentrations of lidocaine are approximately 1.5±5 mg l ±1 , while 60±80% of lidocaine is protein bound. 34 Therefore, the therapeutic free plasma concentration of lidocaine is not higher than 2 mg ml ±1 (range: 0.3± 2 mg ml ±1 ); 1.7 mg ml ±1 lidocaine thus corresponds to high clinically achievable plasma concentrations, while the higher concentration of 17 mg ml ±1 is in the clinically toxic range. It could be argued that plasma-bound lidocaine in a blood-perfused model could still exert its antioxidant properties, but having studied a concentration of 17 mg ml ±1 , we can now exclude the possibility that this could have had an effect on reperfusion injury.
Lidocaine reduces neutrophil adherence in vitro 35 and in vivo. 36 It also reduces lysosomal enzyme release and superoxide anion production by these in¯ammatory cells. 37 A role for in®ltrating leucocytes has been proposed in the development of reperfusion injury. 38 As we used cell-free saline perfusion, an effect of lidocaine on reperfusion injury in a blood-perfused heart cannot be completely excluded.
In summary, we found that lidocaine at a clinically relevant concentration (and a 10-fold higher concentration) protects the myocardium from ischaemic injury, but not from myocardial reperfusion injury. The known cardioprotective effects of lidocaine in ischaemia±reperfusion situations appear to be a consequence of anti-ischaemic properties only and not of reduction in myocardial reperfusion injury. Therefore, we suggest that post-ischaemic lidocaine treatment does not seem to be advantageous in terms of reduction of myocardial necrosis and improvement of recovery after ischaemia. 
